CEACAM5 and colorectal carcinoma: SEPT9 DNA methylation in plasma shows high sensitivity (60–80%) and specificity (80–99%) in identifying stage I and II disease and outperforms both carcinoembryonic antigen (CEA) and fecal occult blood tests for CRC detection.